---
title: "Cryo-Cell net income jumps 70% to $1.27 million in fiscal Q3; revenue flat at $7.82 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301437639.md"
description: "Cryo-Cell reported a 70% increase in fiscal Q3 2026 net income to $1.27 million, with EPS rising to $0.16. However, revenue remained flat at $7.82 million, slightly down from the prior year. The company continues to store over 250,000 cord blood and tissue specimens globally."
datetime: "2026-10-09T20:30:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301437639.md)
  - [en](https://longbridge.com/en/news/301437639.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301437639.md)
generator: "portal-rs"
---

# Cryo-Cell net income jumps 70% to $1.27 million in fiscal Q3; revenue flat at $7.82 million

-   Cryo-Cell posted fiscal Q3 2026 net income of $1.27 million, up 70% from a year earlier. \* Basic and diluted EPS rose to $0.16 from $0.09 in the year-ago quarter. \* Revenue slipped to $7.82 million from $7.83 million in fiscal Q3 2025. \* Business update: the company said it stores more than 250,000 cord blood and cord tissue specimens through its global affiliates. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cryo-Cell International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610091630BIZWIRE\_USPR\_\_\_\_\_20261009\_BW917431) on October 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CCEL.US](https://longbridge.com/en/quote/CCEL.US.md)

## Related News & Research

- [CRYO CELL INTERNATIONAL 3Q FY2026: Revenue $7.82M, 10-Q Summary](https://longbridge.com/en/news/301438966.md)
- [CCEL: Revenue and net income declined, with expansion paused due to Duke arbitration and NYSE compliance risks](https://longbridge.com/en/news/292814054.md)
- [Meta Earnings Preview: Muse, AI Capex and Q3 Outlook](https://longbridge.com/en/news/302318608.md)
- [Summit Therapeutics opens Phase II trial of ivonescimab regimens in advanced kidney cancer](https://longbridge.com/en/news/302278371.md)
- [Micron Technology, Inc. $MU Holdings Reduced by Jackson Square Capital LLC](https://longbridge.com/en/news/302313721.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**